These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 11426552)

  • 1. First line therapy with fludarabine combinations in 42 patients with either post myelodysplastic syndrome or therapy related acute myeloid leukaemia.
    Clavio M; Gatto S; Beltrami G; Cerri R; Carrara P; Pierri I; Canepa L; Miglino M; Balleari E; Masoudi B; Damasio E; Ghio R; Sessarego M; Gobbi M
    Leuk Lymphoma; 2001 Jan; 40(3-4):305-13. PubMed ID: 11426552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
    Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
    Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of "poor risk" acute myeloid leukemia with fludarabine, cytarabine and G-CSF (flag regimen): a single center study.
    Carella AM; Cascavilla N; Greco MM; Melillo L; Sajeva MR; Ladogana S; D'Arena G; Perla G; Carotenuto M
    Leuk Lymphoma; 2001 Jan; 40(3-4):295-303. PubMed ID: 11426551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
    Visani G; Tosi P; Zinzani PL; Manfroi S; Ottaviani E; Testoni N; Clavio M; Cenacchi A; Gamberi B; Carrara P
    Leukemia; 1994 Nov; 8(11):1842-6. PubMed ID: 7526088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk myeloid malignancies.
    de la Rubia J; Regadera A; Martín G; Cervera J; Sanz G; Martínez J; Jarque I; García I; Andreu R; Moscardó F; Jiménez C; Mollá S; Benlloch L; Sanz M
    Leuk Res; 2002 Aug; 26(8):725-30. PubMed ID: 12191567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia.
    Parker JE; Pagliuca A; Mijovic A; Cullis JO; Czepulkowski B; Rassam SM; Samaratunga IR; Grace R; Gover PA; Mufti GJ
    Br J Haematol; 1997 Dec; 99(4):939-44. PubMed ID: 9432047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fludarabine, cytosine arabinoside, granulocyte-colony stimulating factor with or without idarubicin in the treatment of high risk acute leukaemia or myelodysplastic syndromes.
    Virchis A; Koh M; Rankin P; Mehta A; Potter M; Hoffbrand AV; Prentice HG
    Br J Haematol; 2004 Jan; 124(1):26-32. PubMed ID: 14675405
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/- all-trans retinoic acid +/- granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Estey EH; Thall PF; Pierce S; Cortes J; Beran M; Kantarjian H; Keating MJ; Andreeff M; Freireich E
    Blood; 1999 Apr; 93(8):2478-84. PubMed ID: 10194425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.
    Ossenkoppele GJ; Graveland WJ; Sonneveld P; Daenen SM; Biesma DH; Verdonck LF; Schaafsma MR; Westveer PH; Peters GJ; Noordhuis P; Muus P; Selleslag D; van der Holt B; Delforge M; Löwenberg B; Verhoef GE;
    Blood; 2004 Apr; 103(8):2908-13. PubMed ID: 15070662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Current and new therapeutic strategies in acute myeloid leukemia].
    Naito K; Ohnishi K
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):292-6. PubMed ID: 15791811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients.
    Clavio M; Gatto S; Beltrami G; Quintino S; Canepa L; Pierri I; Galbusera V; Carrara P; Miglino M; Varaldo R; Ballerini F; Venturino C; Cerri R; Risso M; Balleari E; Carella AM; Sessarego M; Ghio R; Bacigalupo A; Gobbi M
    J Exp Clin Cancer Res; 2002 Dec; 21(4):481-7. PubMed ID: 12636093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose cytarabine, homoharringtonine and granulocyte colony-stimulating factor priming regimen on patients with advanced myelodysplastic syndrome or acute myeloid leukemia transformed from myelodysplastic syndrome.
    Wu L; Li X; Su J; Chang C; He Q; Zhang X; Xu L; Song L; Pu Q
    Leuk Lymphoma; 2009 Sep; 50(9):1461-7. PubMed ID: 19672772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia.
    Montillo M; Mirto S; Petti MC; Latagliata R; Magrin S; Pinto A; Zagonel V; Mele G; Tedeschi A; Ferrara F
    Am J Hematol; 1998 Jun; 58(2):105-9. PubMed ID: 9625576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of fludarabine in the treatment of acute myeloid leukemia.
    Jackson GH
    Hematol J; 2004; 5 Suppl 1():S62-7. PubMed ID: 15079154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
    Fleischhack G; Hasan C; Graf N; Mann G; Bode U
    Br J Haematol; 1998 Aug; 102(3):647-55. PubMed ID: 9722289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
    Pawson R; Potter MN; Theocharous P; Lawler M; Garg M; Yin JA; Rezvani K; Craddock C; Rassam S; Prentice HG
    Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG).
    Ferrara F; Palmieri S; Pocali B; Pollio F; Viola A; Annunziata S; Sebastio L; Schiavone EM; Mele G; Gianfaldoni G; Leoni F
    Eur J Haematol; 2002 Apr; 68(4):203-9. PubMed ID: 12071935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.